Form 4: Verastem CEO Sells Shares Under 10b5-1 Plan

Verastem, Inc. President and CEO, Dan Paterson, reported the sale of 6,000 shares of common stock over three days in December 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Dan Paterson, President and CEO, and Director of Verastem, Inc. [VSTM], reported transactions involving the company's common stock.
• A total of 6,000 shares of Verastem Common Stock were sold.
• Sales occurred on December 2, 2025 (2,000 shares at $10.32), December 3, 2025 (2,000 shares at $10.00), and December 4, 2025 (2,000 shares at $10.00).
• The aggregate value of shares sold across these three transactions was $60,640.
• These sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Mr. Paterson beneficially owns 420,818 shares of Common Stock.

Sentiment

Score: 5

Explanation: The sale of shares by the CEO is a routine transaction executed under a pre-arranged 10b5-1 trading plan, which typically mitigates concerns about insider selling based on new information, leading to a neutral sentiment.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction not based on new, non-public information.

Negatives

• A reduction in direct beneficial ownership by a key executive, potentially signaling a decrease in insider alignment, although mitigated by the 10b5-1 plan.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, which could be perceived as a slight decrease in alignment, though the 10b5-1 plan suggests a planned diversification rather than a lack of confidence.

Key Dates

Recommendation

The reported sales by the CEO are part of a pre-established Rule 10b5-1 trading plan, which suggests these are routine, planned transactions for personal financial management rather than a reaction to new company developments. While insider selling can sometimes be a negative signal, the 10b5-1 context typically neutralizes such concerns. Therefore, this filing alone does not provide a strong basis for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

Verastem, VSTM, Dan Paterson, insider trading, Form 4, stock sale, 10b5-1 plan, CEO, director, common stock